RESEARCH ARTICLE


A 51-Year Old Woman with Schnitzler Syndrome Treated with Canakinumab



Simon Francis Thomsen*, 1, Pernille Hurup Duhn2, Johannes Kristensen1
1 Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark
2 Department of Rheumatology, Rigshospitalet, Copenhagen, Denmark


Article Metrics

CrossRef Citations:
2
Total Statistics:

Full-Text HTML Views: 582
Abstract HTML Views: 1446
PDF Downloads: 884
Total Views/Downloads: 2912
Unique Statistics:

Full-Text HTML Views: 331
Abstract HTML Views: 868
PDF Downloads: 570
Total Views/Downloads: 1769



Creative Commons License
© 2011 Thomsen et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Dermatology, Bispebjerg Hospital, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark; Tel: +45 2613 9838; Fax: +45 3531 3113; E-mail: sft@city.dk


Abstract

Schnitzler syndrome is a rare auto-inflammatory disorder characterized by urticarial skin rash, a monoclonal IgM component and at least two of the following findings: periodic fever, arthralgias or arthritis, bone pain, palpable lymph nodes, liver or spleen enlargement, elevated erythrocyte sedimentation rate, leukocytosis, and abnormal findings on bone morphologic investigations. We present the first case of Schnitzler syndrome successfully treated with Canakinumab, a novel anti-IL-1-beta monoclonal antibody.

Keywords: Schnitzler syndrome, Canakinumab, Autoinflammatory diseases.